Alkem Laboratories is one of India's largest pharmaceutical formulations companies, with a dominant domestic branded-generics franchise, a growing US generics book, and newer bets in MedTech (Occlutech) and biosimilars/CDMO (Enzene). This quarter's print will speak to whether the 20-21% FY27 EBITDA margin guide holds against API cost pressure on a 23.0% year-ago base, and how the first full consolidation of Occlutech lands alongside the Daman USFDA OAI overhang.
| Results date | November 12, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 37,402 Mn (+10.9% YoY) |
| Previous quarter PAT | Rs. 5,200 Mn after Non-Controlling Interest (-21.7% YoY) |
| Previous quarter EBITDA margin | 20.5% |
| Market cap | Rs. 63,333.58 Cr |
| CMP | Rs. 5,297.0 |
The board meets on November 12, 2026 to consider and approve the Q2/H1 FY27 financial results, per the November 4, 2026 intimation to the exchanges.
The Q2 FY27 earnings call is scheduled for November 12, 2026, 4:30-5:30 pm IST, hosted by Motilal Oswal Securities. Participants include Sandeep Singh (MD), Dr. Amrut Naik (CEO) and Dishant Hitesh Doshi (Deputy CFO).
The quarter's central test is the margin bridge: Q1 FY27 printed a 20.5% EBITDA margin with EBITDA up only +3.7% YoY against +10.9% revenue growth, and the FY27 guide of 20-21% now has to be defended against a 23.0% year-ago base.
On the ground, the domestic market ran at double-digit value growth through the quarter (IPM +13.6% in July, +10.7-12.96% in August per IQVIA/Pharmarack), with Alkem's August IPM growth of 13.9% at Rs. 996 cr suggesting the guided 100-150 bps spread above market is being held, even as market volume growth cooled to 1.1% in August and anti-infectives grew only 2.7%.
API costs are the stated pressure point: WPI for basic pharmaceutical products rose +3.40% YoY in August with Gujarat shortage reporting and molecule-level spikes such as paracetamol API roughly doubling to Rs. 550-650/kg, pressing against the guided 66.5-67% gross margin after Q1's 67.9% print.
Occlutech consolidates for the first full quarter (closed July 16, 2026) against the ~Rs. 400 Cr (8.5-month) FY27 sales guide that management has already flagged will be "a bit off from the guidance which was last said", while Enzene CDMO spend continues at ~Rs. 60 Cr per quarter ahead of the FY28 breakeven target.
The tax line is the other swing factor, with the 30-32% consolidated FY27 guide (revised down from 35-38%) needing reconciliation after Q1's effective rate drove the -21.7% PAT decline, and the rupee's ~2% weakening through the quarter to near 97/$ is a tailwind to the US book (20.0% of sales) where management has flagged "no volume growth".
Guidance scorecard to interrogate: The FY27 guidance framework faces its first full-quarter test on multiple fronts.
Domestic spread and trade generics recovery
US business quality and Daman overhang
Strategic and organizational items
Biosimilar launch timelines
Management attributed the slowdown to industry-wide competition plus internal factors — tightened credit policies, API-cost-driven price increases, and lower market inventories. April-June was flat YoY, with recovery expected in upcoming quarters.
Management has guided to breakeven in FY28, requiring annualized revenues of USD 25-30 million, with the USD 30 million revenue expectation sitting in 2027-28. Quarterly expenses currently run at Rs. 60 crores.
Management has guided FY27 EBITDA margin at 20-21%, with Q1 FY27 printing 20.5%. The company has also stated at least 1% YoY margin improvement from FY27 onwards, though it flagged it is struggling to maintain the 100 bps annual improvement due to geopolitical instability and inflationary pressures.
Management said US entry for the Denosumab biosimilars is expected at end-2026, delayed by the ongoing Amgen litigation. The Europe Xgeva launch was anticipated in about 3 months as of the Q1 FY27 call.
Revenue rose +10.9% YoY to Rs. 37,402 Mn in Q1 FY27, with India sales up +10.3% and non-US international up +34.5%. Alkem's August 2026 IPM growth of 13.9% ran above the market print in the same month.
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.